

Instance: composition-en-688b37e07e24bb84319b90f5bb16c864
InstanceOf: CompositionUvEpi
Title: "Composition for carbaglu Package Leaflet"
Description:  "Composition for carbaglu Package Leaflet"
Usage: #example

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - carbaglu"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Carbaglu is and what it is used for </li>
<li>What you need to know before you take Carbaglu </li>
<li>How to take Carbaglu </li>
<li>Possible side effects </li>
<li>How to store Carbaglu </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What carbaglu is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What carbaglu is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Carbaglu can help eliminating excessive ammonia plasma levels (elevated ammonia level in the 
blood). Ammonia is especially toxic for the brain and leads, in severe cases, to reduced levels of 
consciousness and to coma. 
Hyperammonaemia may be  due to 
  the lack of a specific liver enzyme N- acetylglutamate synthase. Patients with this rare disorder 
are not able to eliminate nitrogen waste, which builds up after eating protein. </p>
<p>This disorder persists during the entire life of the affected patient and therefore the need for this </p>
<p>treatment is lifelong. 
  isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia. Patients suffering from 
one of these disorders need treatment during the hyperammonaemia crisis. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take carbaglu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take carbaglu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Carbaglu 
if you are allergic to carglumic acid or any of the other ingredients of Carbaglu (listed in section 6). 
Do not take Carbaglu during breast-feeding </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Carbaglu.  </p>
<p>Carbaglu treatment should be initiated under the supervision of a physician experienced in the 
treatment of metabolic disorders. </p>
<p>Your doctor will evaluate your individual responsiveness to carglumic acid before initiating any long 
term treatment.<br />
The dose should be individually adjusted in order to maintain normal ammonia plasma levels. </p>
<p>Your doctor may prescribe supplemental arginine or restrict your protein intake. </p>
<p>In order to follow-up your condition and your treatment, your doctor may examine your liver, your 
kidneys, your heart and your blood on a regular basis. </p>
<p>Other medicines and Carbaglu 
Tell your doctor or pharmacist if you are taking,  have recently taken or might take any other 
medicines. </p>
<p>Carbaglu with food and drink 
Carbaglu must be taken orally before meals or feedings. 
The tablets must be dispersed in a minimum of 5 to 10 ml of water and taken immediately. The 
suspension has a slightly acidic taste. </p>
<p>Pregnancy and Breast-feeding 
The effects of Carbaglu on pregnancy and the unborn child are not known.<br />
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>The excretion of carglumic acid into breast milk has not been studied in women. Nevertheless, as 
carglumic acid has been shown to be present in the milk of lactating rats with potential toxic effects 
for their fed pups, you should not breast feed your baby if you are taking Carbaglu. </p>
<p>Driving and using machines 
Effects on the ability to drive and use machines are not known. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take carbaglu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take carbaglu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>The usual dose: 
The initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of 250 mg per 
kilogram of body weight (for example, if you weight 10kg, you should take 1g per day, or 5 tablets), 
For patients suffering from N-acetylglutamate synthase deficiency, in the long term, the daily dose 
usually ranges from 10 mg to 100 mg per kilogram of body weight.  </p>
<p>Your doctor will determine the dose suitable to you in order to maintain normal ammonia levels in 
your blood. </p>
<p>Carbaglu should ONLY be administered by mouth or via a feeding tube into the stomach (using a 
syringe, if necessary). </p>
<p>When the patient is in hyperammonaemic coma, Carbaglu is administered by fast push through a 
syringe via the tube set up and used to feed you. </p>
<p>Tell your doctor in case you are suffering from renal impairement. Your daily dose should be reduced. </p>
<p>If you take more Carbaglu than you should 
Ask your doctor or pharmacist for advice. </p>
<p>If you forget to take Carbaglu 
Do not take a double dose to make up for forgotten doses. </p>
<p>If you stop taking Carbaglu 
Do not stop Carbaglu without informing your doctor. 
If you have any further questions on the use of this product, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The following side effects were reported as follows: very common (may affect more than 1 in people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), 
rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people) and not 
known (frequency cannot be estimated from the available data). </p>
<ul>
<li>Common: increased sweating </li>
<li>Uncommon: bradycardia (decreased frequency of the heart), diarrhoea, fever, increased 
transaminases, vomiting </li>
<li>Not known: rash </li>
</ul>
<p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please 
tell your doctor or pharmacist. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store carbaglu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store carbaglu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the tablet container after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C   8 C). </p>
<p>After first opening of the container: do not refrigerate, do not store above 30 C. 
Keep the container tightly closed in order to protect from moisture. 
Write the date of opening on the tablet container. Discard 3 months after first opening. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how 
to throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Carbaglu contains<br />
- The active substance is carglumic acid. Each tablet contains 200 mg of carglumic acid. 
- The other ingredients are microcrystalline cellulose, sodium laurilsulfate, hypromellose, 
croscarmellose sodium, silica colloidal anhydrous, sodium stearyl fumarate. </p>
<p>What Carbaglu looks like and contents of the pack 
Carbaglu 200mg tablet is a bar-shaped tablet, with 4 punches on one side with 3 break-mark sides. 
Carbaglu is presented in a plastic container of 5, 15 and 60 tablets which is closed with a child 
resistant cap.  </p>
<p>Marketing Authorisation Holder 
Recordati Rare Diseases 
Immeuble  Le Wilson<br />
70, avenue du G n ral de Gaulle 
F-92800 Puteaux 
France 
Tel: + 33 1 4773 6Fax: + 33 1 4900 1Manufacturer 
Recordati Rare Diseases 
Immeuble  Le Wilson<br />
70, Avenue du G n ral de Gaulle 
F-92800 Puteaux 
France </p>
<p>or </p>
<p>Recordati Rare Diseases 
Eco River Parc 
30, rue des Peupliers 
F-92000 Nanterre 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgique/Belgi /Belgien 
Recordati 
T l/Tel: +32 2 46101 Lietuva 
Recordati AB. 
Tel: + 46 8 545 80  vedija </p>
<p>Recordati Rare Diseases 
Te .: +33 (0)1 47 73 64    </p>
<p>Luxembourg/Luxemburg 
Recordati 
T l/Tel: +32 2 46101 Belgique/Belgien </p>
<p>esk  republika 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francie </p>
<p>Magyarorsz g 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Franciaorsz g  </p>
<p>Danmark 
Recordati AB. 
Tlf : +46 8 545 80 Sverige </p>
<p>Malta 
Recordati Rare Diseases 
Tel: +33 1 47 73 64 Franza  </p>
<p>Deutschland 
Recordati Rare Diseases Germany GmbH 
Tel: +49 731 140 554 0 
Nederland 
Recordati 
Tel: +32 2 46101 Belgi  </p>
<p>Eesti 
Recordati AB. 
Tel: + 46 8 545 80 Rootsi 
Norge 
Recordati AB. 
Tlf : +46 8 545 80 Sverige  </p>
<p>Recordati Hellas 
 : +30 210 6773 sterreich 
Recordati Rare Diseases Germany GmbH 
Tel: +49 731 140 554 0 
Deutschland </p>
<p>Espa a 
Recordati Rare Diseases Spain S.L.U. 
Tel: + 34 91 659 28 Polska 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francja  </p>
<p>France 
Recordati Rare Diseases 
T l: +33 (0)1 47 73 64 Portugal 
Jaba Recordati S.A. 
Tel: +351 21 432 95 Hrvatska 
Recordati Rare Diseases 
T l: +33 (0)1 47 73 64 Francuska </p>
<p>Rom nia 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Fran a  </p>
<p>Ireland 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 France 
Slovenija<br />
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francija  </p>
<p>sland 
Recordati AB. 
Simi:+46 8 545 80 Sv j  </p>
<p>Slovensk  republika 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Franc zsko  </p>
<p>Italia 
Recordati Rare Diseases Italy Srl 
Tel: +39 02 487 87 Suomi/Finland 
Recordati AB. 
Puh/Tel : +46 8 545 80 Sverige </p>
<p>Recordati Rare Diseases 
  : +33 1 47 73 64   </p>
<p>Sverige 
Recordati AB. 
Tel : +46 8 545 80 Latvija 
Recordati AB. 
Tel: + 46 8 545 80 Zviedrija </p>
<p>United Kingdom (Northern Ireland) 
Recordati Rare Diseases UK Ltd. 
Tel: +44 (0)1491 414This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

